Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor
- PMID: 18354214
- DOI: 10.4049/jimmunol.180.7.4901
Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor
Abstract
MUC1 is a highly attractive immunotherapeutic target owing to increased expression, altered glycosylation, and loss of polarity in >80% of human cancers. To exploit this, we have constructed a panel of chimeric Ag receptors (CAR) that bind selectively to tumor-associated MUC1. Two parameters proved crucial in optimizing the CAR ectodomain. First, we observed that the binding of CAR-grafted T cells to anchored MUC1 is subject to steric hindrance, independent of glycosylation status. This was overcome by insertion of the flexible and elongated hinge found in immunoglobulins of the IgD isotype. Second, CAR function was highly dependent upon strong binding capacity across a broad range of tumor-associated MUC1 glycoforms. This was realized by using an Ab-derived single-chain variable fragment (scFv) cloned from the HMFG2 hybridoma. To optimize CAR signaling, tripartite endodomains were constructed. Ultimately, this iterative design process yielded a potent receptor termed HOX that contains a fused CD28/OX40/CD3zeta endodomain. HOX-expressing T cells proliferate vigorously upon repeated encounter with soluble or membrane-associated MUC1, mediate production of proinflammatory cytokines (IFN-gamma and IL-17), and elicit brisk killing of MUC1(+) tumor cells. To test function in vivo, a tumor xenograft model was derived using MDA-MB-435 cells engineered to coexpress MUC1 and luciferase. Mice bearing an established tumor were treated i.p. with a single dose of engineered T cells. Compared with control mice, this treatment resulted in a significant delay in tumor growth as measured by serial bioluminescence imaging. Together, these data demonstrate for the first time that the near-ubiquitous MUC1 tumor Ag can be targeted using CAR-grafted T cells.
Similar articles
-
T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.Biochim Biophys Acta. 2014 Jan;1840(1):378-86. doi: 10.1016/j.bbagen.2013.09.029. Epub 2013 Sep 27. Biochim Biophys Acta. 2014. PMID: 24076235
-
CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth.Front Immunol. 2019 May 24;10:1149. doi: 10.3389/fimmu.2019.01149. eCollection 2019. Front Immunol. 2019. PMID: 31178870 Free PMC article.
-
Targeting of Tumor-Associated Glycoforms of MUC1 with CAR T Cells.Immunity. 2016 Nov 15;45(5):945-946. doi: 10.1016/j.immuni.2016.10.014. Immunity. 2016. PMID: 27851917
-
CAR mechanics: driving T cells into the MUC of cancer.Cancer Res. 2009 Jun 1;69(11):4559-62. doi: 10.1158/0008-5472.CAN-09-0564. Cancer Res. 2009. PMID: 19487277 Review.
-
Recent advances in tumor associated carbohydrate antigen based chimeric antigen receptor T cells and bispecific antibodies for anti-cancer immunotherapy.Semin Immunol. 2020 Feb;47:101390. doi: 10.1016/j.smim.2020.101390. Epub 2020 Jan 22. Semin Immunol. 2020. PMID: 31982247 Free PMC article. Review.
Cited by
-
The Great War of Today: Modifications of CAR-T Cells to Effectively Combat Malignancies.Cancers (Basel). 2020 Jul 24;12(8):2030. doi: 10.3390/cancers12082030. Cancers (Basel). 2020. PMID: 32722109 Free PMC article. Review.
-
Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling.J Clin Immunol. 2012 Oct;32(5):1059-70. doi: 10.1007/s10875-012-9689-9. Epub 2012 Apr 17. J Clin Immunol. 2012. PMID: 22526592
-
Strategies to Address Chimeric Antigen Receptor Tonic Signaling.Mol Cancer Ther. 2018 Sep;17(9):1795-1815. doi: 10.1158/1535-7163.MCT-17-1097. Mol Cancer Ther. 2018. PMID: 30181329 Free PMC article. Review.
-
CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success.Front Immunol. 2018 Dec 3;9:2740. doi: 10.3389/fimmu.2018.02740. eCollection 2018. Front Immunol. 2018. PMID: 30559740 Free PMC article. Review.
-
Advances in MUC1-Mediated Breast Cancer Immunotherapy.Biomolecules. 2022 Jul 6;12(7):952. doi: 10.3390/biom12070952. Biomolecules. 2022. PMID: 35883508 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous